Andrew Weinberg

Andrew Weinberg

Company: AgonOx

Job title: Chief Scientific Officer


Enriching for Tumor-Reactive CD8 TIL with CD39/103 Markers: Implications for TIL Therapy 2:00 pm

CD39 and CD103 DP CD8 TIL highly enrich for tumor-specificity Reactivity and recovery of function is associated with a 1-2 week incubation period Discuss how these T cells represent a natural and diverse TCR repertoire to tumor antigens and can be found in most solid malignancies, although frequencies varyRead more

day: Conference Day 1

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.